Joshua Horn

Joshua Horn

May 07, 2024 | The Legal Intelligencer

Unworthy Medical Marijuana Dispensaries and the Importance of Weeding Them Out

The goal of the MMA is to "provide a program of access to medical marijuana which balances the need of patients to have access to the latest treatments with the need to promote patient safety" and to "provide a safe and effective method of delivery of medical marijuana to patients."

By Joshua Horn and Brooke Hurlbrink

6 minute read

May 18, 2023 | The Legal Intelligencer

A Name Is Just a Name, Unless It Is a Strain Name

This article outlines what the department is doing, why its conduct may raise concerns given state rulemaking obligations, and how that could harm Pennsylvanians in the state's medical marijuana program.

By Joshua Horn and Robert H. Eisentrout

8 minute read

July 11, 2022 | New York Law Journal

Selling Hemp Futures: The Sky May Be the Limit

CBD and hemp businesses may consider minimizing the need for CFTC and NFA registration, and onerous registration and disclosure requirements if structured correctly.

By Ernest Edward Badway and Joshua Horn

11 minute read

May 13, 2022 | The Legal Intelligencer

US Investments in Foreign Cannabis: Unspoken Safe Harbor or Federal Tripwire?

The nascent cannabis industry opens up just as many risks as it does opportunities. Anyone considering investments touching on that industry would be wise to stop and investigate the opportunity carefully before signing on the dotted line.

By Joshua Horn and Saverio S. Romeo

6 minute read

December 31, 2019 | The Legal Intelligencer

The Growth of Hemp in the US—an Ever-Changing Regulatory Environment

The emergence of the hemp crop in U.S. markets has been slowed by a confusing and inconsistent regulatory environment at both the state and federal levels.

By Joshua Horn and Jesse Harris

6 minute read

June 25, 2019 | The Legal Intelligencer

FDA Hearing on Cannabis Products—CBD Takes Center Stage

While the president and Congress gave hemp the go-ahead, it is now on the regulators to take the next step. The FDA has authority to regulate cannabis-derived compounds, including CBD, under the Federal Food, Drug, and Cosmetic Act. So far, though, the FDA has not done much regulating in regards to CBD.

By Joshua Horn and Ellis W. Martin

7 minute read

June 21, 2019 | New Jersey Law Journal

The 2018 Farm Bill, Hemp and Interstate Commerce

Among other things, the 2018 Farm Bill removed hemp from the Controlled Substances Act, unlocking a new industry that is poised to make serious waves throughout the agricultural sector and beyond.

By Joshua Horn and Jesse M. Harris

8 minute read

May 23, 2018 | The Legal Intelligencer

Cannabis and Banks: What Qualifies as Illegal Activity?

Many legal issues arise out of financing cannabis activities, not the least of which is whether a target property for a cannabis venture is mortgaged by a bank. The standard institutional mortgage contains language that allows the mortgagee to “call” the loan if the property is being used to conduct “illegal activity.”

By Joshua Horn and Jesse M. Harris

6 minute read

August 01, 2006 | The Legal Intelligencer

The Unfulfilled Qwest For a 'Selective Waiver'

Faced with the prospect of ever-increasing governmental/regulatory investigations, companies are frequently confronted with the opportunity to disclose information to federal agencies for various reasons, including the possibility of more favorable treatment. A dilemma arises when that production requires the disclosure of information protected by the attorney-client privilege or work-product doctrine.

By Joshua Horn and Beth L. Domenick

7 minute read

August 08, 2008 | Law.com

A Creative Screening of Electronically Stored Information May Determine the Victor

Electronically stored information (?ESI?) is not an issue that can be put on the back burner and dealt with in a piecemeal fashion after litigation ensues. The painful results of such an approach were the subject of Magistrate Judge Grimm?s recent decision in Victor Stanley, Inc. v. Creative Pipe, Inc., et al.

By Joshua Horn and Beth L. Domenick

11 minute read